CRISPR reveals genes essential to the success of immunotherapy

Why do some patients respond to certain cancer treatments, while others simply do not?

Researchers investigating immunotherapy and T-cell resistant cancers are using genomic tools in new ways. A team of scientists have harnessed the specificity of CRISPR, a gene-editing technology, to ‘knock out’ every one of the 19,000 protein-encoding genes of human melanoma cells. These genetically modified melanoma cells were then tested for their response to T-cell Therapy.

Researchers found over 100 genes whose presence in cancer cells potentially dictates the success of T-cells in destroying cancer cells. Many of these identified genes have been further associated with tumor cytolytic activity potentially bringing clinicians another few steps closer to effective cancer treatment.

Read more: Nature / Science Daily / UPI

Image: Neu Paddy / CC0 Creative Commons

This story is taken from the 11 August 2017 edition of The Warren Centre’s Prototype newsletter. Sign up for the Prototype here.